METASTATIC BREAST CANCER

This study tests an experimental oral drug called PMD-026 in people with metastatic breast cancer (cancer that has spread). The drug targets a protein called RSK2 to kill cancer cells. The trial involves about 61 participants and aims to check the drug's safety and how well it wo…

This study is for people with breast cancer that has spread to only a few places in the body (oligometastasis). It tests whether adding targeted treatments like radiation or surgery to standard therapy can help people live longer. About 340 participants will first receive 12 week…

This study is for people with metastatic breast cancer (cancer that has spread). It aims to see if choosing treatments based on specific tumor markers (biomarkers) can help control the disease longer. About 700 participants will receive standard therapies matched to their biomark…

This early-phase study tests a new drug called BGB-43395, which blocks a protein (CDK4) that helps cancer cells grow. It is for people with advanced HR+/HER2- breast cancer or other solid tumors that have spread. The main goal is to find the safest and most effective dose, either…

This early-phase study tests a new drug called IPH5301 in people with advanced solid tumors that have spread. The drug works by blocking a protein (CD73) that tumors use to hide from the immune system. The study first finds the safest dose of IPH5301 alone, then tests it combined…

This study tests whether adding belzutifan to fulvestrant works better than standard treatments for people with a common type of advanced breast cancer (ER+/HER2-) that has worsened after hormone therapy. About 120 adults will receive either the new combination or a standard drug…

This study tests a new way of giving already-approved drugs to people with hormone-positive metastatic breast cancer. The goal is to see if using the drugs in a specific order can better control the cancer and possibly lead to no evidence of disease. The study will include 15 wom…

This early-stage study tests a new drug called HLD-0117 in about 33 women with a type of advanced breast cancer (ER-positive) that has spread and stopped responding to standard treatments. The main goals are to check the drug's safety and find the right dose. Researchers will als…

This study follows about 1,155 adults with HER2-low breast cancer that cannot be removed by surgery or has spread to other parts of the body. It compares how long people stay on a newer targeted drug (trastuzumab deruxtecan) versus standard chemotherapy before needing a different…

This study is for people with a certain type of advanced breast cancer (HR+ HER2-). It uses a blood test to measure a marker called TKa early in treatment. If the marker doesn't drop enough, doctors may switch to a different therapy sooner. The goal is to see if this approach hel…

This early-phase study is for people with metastatic HR+ HER2- breast cancer that has spread to the bone. Researchers want to find the best dose of the drug abemaciclib when given together with radiation and hormone therapy. The goal is to control the disease and manage side effe…

This study tests whether the drugs enzalutamide (alone or with mifepristone) can control advanced breast cancer that is androgen receptor-positive and triple-negative or ER-low. About 201 participants will receive either the study drugs or standard chemotherapy. The goal is to se…

This early-phase study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple-negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants with advance…

This study tests two experimental drugs, BNT323 and BNT327, together in people with advanced breast cancer that has spread or cannot be removed. The goal is to see if the combination can shrink tumors and control the disease. About 380 adults with specific HER2-positive, HER2-low…

This study tests a new combination of drugs (alpelisib, L-NMMA, and chemotherapy) in people with a rare and aggressive type of breast cancer called metaplastic breast cancer that has spread or cannot be removed by surgery. The goal is to see if the combination is safe and can shr…

This early-phase study tests a new drug called BBO-10203 in people with advanced solid tumors (breast, colorectal, or lung cancer) that have not responded to standard treatments. The drug works by blocking a key cancer growth signal (PI3Kα:RAS). The main goals are to find a safe …

This study is for people with ER-positive, HER2-negative metastatic breast cancer that has spread and cannot be removed by surgery. Researchers want to see if combining three drugs—lenvatinib, pembrolizumab, and fulvestrant—is safe and can shrink tumors. About 54 adults will take…

This study tests a new drug called HRS-8080 in 240 women with advanced breast cancer that has worsened after hormone therapy. Participants will either receive HRS-8080 or another treatment chosen by their doctor. The main goal is to see if HRS-8080 can delay cancer growth longer …

This study tests a new drug, evexomostat, added to two standard treatments for a common type of advanced breast cancer (HR+, HER2-). The goal is to see if the combination is safe and can reduce severe blood sugar spikes caused by the standard drugs. About 52 adults with specific …

This study tests a drug called alisertib combined with hormone therapy for people with a common type of advanced breast cancer (HR+, HER2-). The goal is to find the best dose and see if the combination can shrink tumors or slow the disease. About 150 adults whose cancer has worse…

This study tests whether adding the arthritis drug tocilizumab to standard chemotherapy helps shrink tumors or delay cancer growth in people with metastatic triple-negative or ER-low breast cancer. The trial includes both Black and non-Black participants to see if the drug works …

This study tests whether adding the drug capivasertib to standard hormone therapy helps people with advanced HR+/HER2- breast cancer stay on treatment longer and maintain quality of life. About 250 adults whose cancer worsened after prior hormone therapy will take capivasertib pl…

This study tests a drug called SHR-A1811 in people with advanced breast cancer that has spread to the brain. It is for those with HER2-positive or HER2-low tumors who have not had radiation to the brain. The goal is to see if the drug can shrink brain tumors and control the cance…

This study is for people with metastatic breast cancer whose disease has started to grow in just a few spots while on their current treatment. It tests whether using precise, high-dose radiation on those spots can allow them to keep using their current medication for at least 6 m…

This study tests a new drug, SKB264, against standard chemotherapy in 430 people with advanced hormone receptor-positive, HER2-negative breast cancer that has stopped responding to hormone therapy. The goal is to see if SKB264 can delay cancer growth or improve survival. Particip…

This early-stage study tests the safety of a new drug called ERX-315 in 15 adults with advanced solid tumors (such as breast, ovarian, or pancreatic cancer) that have stopped responding to approved therapies. The main goal is to find safe doses and watch for side effects, not to …

This phase 3 study tests whether a new drug called palazestrant, combined with ribociclib, works better than the standard treatment (letrozole plus ribociclib) for people with a common type of advanced breast cancer (ER+/HER2-). About 1,000 adults who have not had prior treatment…

This study tests whether adding the immunotherapy drug pembrolizumab, with or without the targeted drug olaparib, to standard radiation therapy is safe and effective for people with metastatic triple-negative or hormone-receptor-positive breast cancer. About 34 participants will …

This study tests a high dose of the chemotherapy drug methotrexate given through a vein in people with breast cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this treatment can help patients live longer than 12 weeks. The trial enrolls adul…

This study tests whether adding surgery and targeted radiation to the usual treatment can help people with HER2-positive breast cancer that has spread to a few other body parts (up to 5 spots). About 178 adults will be randomly assigned to get either standard care alone or standa…

This study tests several new drug combinations containing FWD1802 in people with a common type of advanced breast cancer (ER-positive/HER2-negative) that cannot be removed by surgery or has spread. The study has two parts: first, finding the safest dose (Phase 1), and then checki…

This study tests a new drug, OP-1250, against the usual treatments (fulvestrant or an aromatase inhibitor) in people with a certain type of advanced breast cancer (ER+, HER2-). The goal is to see if OP-1250 can delay cancer growth better than standard care. About 510 adults whose…

This study tests whether combining two drugs—elacestrant and trastuzumab deruxtecan—can shrink tumors in people with a specific type of advanced breast cancer (HR+/HER2-low) that no longer responds to standard hormone therapy or CDK4/6 inhibitors. About 65 participants will recei…

This early-phase study tests a new drug called OP-3136 in people with advanced breast, lung, or prostate cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow cancer growth. About 180 adults will…

This study compares two treatments for advanced estrogen receptor-positive (ER+) breast cancer that has stopped responding to standard therapies. About 297 participants will receive either a combination of elacestrant and capecitabine or capecitabine alone. The goal is to see if …

This study tests a new drug called FWD1802 in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find a safe dose and see if it shrinks tumors. About 99 women with cancer that has spread or cannot be removed by surgery will take part.

This study tests whether adding the drug inavolisib to standard maintenance therapy (Phesgo) can help keep advanced HER2-positive breast cancer with a specific gene mutation (PIK3CA) from getting worse. About 230 adults with this type of breast cancer will receive either the comb…

This study tests a new drug called patritumab deruxtecan in people with advanced breast cancer that is hormone-receptor positive and no longer responds to hormone therapy or CDK4/6 inhibitors. About 99 participants will receive the drug every three weeks to see if it shrinks tumo…

This study tests an experimental drug called EP0062, alone or with standard treatments, in people with a certain type of advanced breast cancer (AR+/HER2-/ER+) that has come back or spread. The main goals are to find the safest dose and see if it helps shrink tumors. About 95 adu…

This study is for people with breast cancer that has spread to the brain (at least two tumors). Participants receive an immunotherapy drug called pembrolizumab every three weeks, plus a precise, one-time radiation treatment to just one of the brain tumors. The goal is to see if t…

This study tests several different drug combinations in people with metastatic breast cancer that has spread or cannot be removed by surgery. The goal is to see which combinations work best to shrink tumors or slow the disease. About 792 adults with various breast cancer types wi…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests if a form of estrogen (estradiol) can help control advanced breast cancer that is hormone-receptor-positive (ER+). It includes 36 post-menopausal women whose cancer has spread or returned and who have already tried other hormone therapies. The goal is to see if w…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations help stop the cancer from growing. About 435 adults will take part in this ear…

This study tests a new drug called SKB264 against standard treatments for people with a common type of advanced breast cancer (HR+/HER2-) that has not responded to at least one chemotherapy. About 376 participants will be randomly assigned to receive either SKB264 or a doctor-cho…

This study tests a lower daily dose of the chemotherapy drug capecitabine in 40 patients aged 60 or older, or those who are frail, with advanced HER2-negative breast cancer. The goal is to see if this gentler approach can still shrink tumors or slow the disease while reducing har…

This early-phase study is testing a new drug called OP-1250 (palazestrant) combined with other targeted therapies for people with advanced or metastatic ER-positive, HER2-negative breast cancer. The main goals are to find the safest dose and understand side effects. About 190 adu…

This study tests whether giving high-precision radiation (SBRT) to all visible tumors can delay cancer worsening in people with 1 to 5 metastases from breast or lung cancer. About 145 participants will be randomly assigned to receive either standard care alone or standard care pl…

This study tests whether giving a precise, high-dose radiation treatment (SBRT) to a single spot where breast cancer has worsened can help keep the disease from spreading further. About 46 adults with metastatic breast cancer (ER+ or HER2+) will continue their usual drug therapy …

This study looks at whether giving antibody-drug conjugates (ADCs) a second time is safe and effective for people with advanced breast cancer that has spread. About 160 adults who have already received ADCs will be enrolled. The goal is to see if the tumors shrink or stop growing…

This study looks at how well the drug inavolisib works for people with a certain type of advanced breast cancer that has stopped responding to hormone therapy. The cancer must have a specific gene change (PIK3CA mutation) and be hormone receptor-positive and HER2-negative. About …

This early-stage trial tests a new radioactive drug called [177Lu]Lu-ABY-271 in people with HER2-positive metastatic breast cancer that cannot be removed by surgery. The main goals are to check safety and see where the drug goes in the body. About 21 participants will take part.

This study tests whether the drug sacituzumab govitecan (SG) can still shrink tumors in people with a certain type of advanced breast cancer (HR+/HER2 low) who have already received a similar drug called T-DXd. About 75 adults will receive SG at its standard dose. The goal is to …

This study compares the hormone therapy elacestrant alone versus elacestrant combined with a CDK4/6 inhibitor (palbociclib, abemaciclib, or ribociclib) in 174 people with ER+/HER2- advanced or metastatic breast cancer who have already used a CDK4/6 inhibitor. The goal is to see i…

This study tests whether a new drug combination (lasofoxifene plus abemaciclib) works better than the current standard (fulvestrant plus abemaciclib) for people with advanced ER+/HER2- breast cancer that has an ESR1 mutation. About 500 adults whose cancer progressed after initial…

This study tests whether a new drug (RLY-2608) combined with fulvestrant works better than another approved combination (capivasertib + fulvestrant) for people with advanced or metastatic HR+/HER2- breast cancer that has a PIK3CA mutation. About 540 adults whose cancer worsened a…

This study tests a new way of giving the chemotherapy drug capecitabine to people with metastatic ER+ breast cancer. Instead of a fixed dose, the dose is adjusted based on how the tumor responds on scans and blood tests. The goal is to control the cancer for as long as possible w…

This early-stage study tests an experimental oral drug called BBI-940 in adults with advanced or metastatic breast cancer. The drug works by breaking down a protein that helps cancer cells grow. It is given alone or with another drug (fulvestrant). The main goals are to check saf…

This study tests whether a combination of three drugs (anastrozole, fulvestrant, and abemaciclib) can shrink or control tumors in people with advanced hormone receptor-positive, HER2-negative breast cancer. About 20 participants will receive the treatment, and researchers will me…

This early-phase study tests the safety of combining two drugs, olaparib and estradiol, in post-menopausal women with advanced ER+/HER2- breast cancer that has spread. The goal is to find the best dose for future studies. Only 6 participants will be enrolled.

This study tests an experimental pill called zongertinib, which blocks HER2—a protein that makes cancer grow. It is for adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and hasn't responded to prior treatments. The study has two parts: first, findi…

This study tests whether a new treatment called Bria-IMT, given with an immunotherapy drug, helps people with advanced metastatic breast cancer live longer compared to standard chemotherapy. It is for patients whose cancer has not responded to available treatments. About 404 adul…

This early-stage study tests a new drug (BGB-21447) combined with standard hormone therapy, with or without another targeted drug, in people with HR+/HER2- breast cancer that has spread. The goal is to find safe doses and see if the combination can shrink tumors. About 120 adults…

This early-stage study tests a new drug, RLY-2608, designed to block a faulty protein in cancer cells with a specific gene change (PIK3CA mutation). It is for adults with advanced solid tumors or certain breast cancers that have not responded to other treatments. The study will t…

This study tests whether a gene test can help doctors pick the right chemotherapy for people with a certain type of advanced breast cancer (HR+ metastatic). About 64 adults whose cancer has stopped responding to hormone therapy will receive a chemo drug called capecitabine. The g…

This study tests whether giving two different antibody drug conjugates (Dato-DXd and T-DXd) one after the other can shrink tumors in people with HER2-negative metastatic breast cancer whose cancer has already progressed after prior antibody drug conjugate therapy. About 357 parti…

This study compares two types of PET scans to see which is better at finding and tracking metastatic lobular breast cancer. About 30 adults with this cancer will receive both an experimental FES PET/CT scan and a standard FDG PET/CT scan. The goal is to improve detection and moni…

This study tests a new type of PET scan that looks for a specific marker (CXCR4) on cancer cells. It involves 12 people with metastatic triple-negative breast cancer. The goal is to see if this scan can find cancer spread as well as the standard scan, which could help doctors cho…

This study is testing a remote program called PRISM that teaches stress management and resilience skills to people recently diagnosed with metastatic breast cancer. The goal is to see if it improves quality of life and possibly survival, especially for Black women who often have …

This study tests whether a 12-week, home-based exercise program (aerobic and resistance training) can reduce cancer-related fatigue in people with metastatic breast cancer who are taking the drug Enhertu. About 80 participants will follow an unsupervised workout routine. The goal…

This study tests a five-session palliative care program designed for people with metastatic breast cancer and their caregivers. The goal is to help patients talk with their doctors about what matters most to them. The study will include 400 participants and aims to make palliativ…

This study is testing a values assessment tool for women with metastatic breast cancer and their caregivers. The goal is to see if the tool helps them feel less conflicted about treatment decisions and improves communication with their doctors. About 40 participants will use the …

This pilot study is for Black and Latina women with stage IV breast cancer. It tests whether a community navigator can help them connect to supportive services like pain management and emotional support. The goal is to see if this approach is practical and helpful for reducing di…

This study explores whether regular video or phone check-ins between patients with advanced breast cancer, their caregivers, and their cancer care teams can improve the hospice experience. About 200 participants receiving in-home hospice care in Massachusetts will take part. The …

This study looks at whether a community-based exercise program called Get Real and Heel can help people with metastatic breast cancer become more physically active. Researchers want to see if the program improves quality of life, physical function, and social support while reduci…

This study looks at whether a special cooling cap can help people with metastatic breast cancer keep more of their hair during chemotherapy. About 120 people will either use the Paxman Scalp Cooling System or not, and researchers will compare hair loss rates and quality of life. …

This study interviews 15 doctors and nurses who care for people with metastatic breast cancer. The goal is to find out if a new computer tool that predicts how the disease may progress is easy to use and helpful. The results will guide how to best bring this tool into everyday ca…

This study tests if a special type of PET/CT scan (FDG-PET/CT) is better than a regular CT scan for monitoring metastatic breast cancer. About 420 adults with newly diagnosed metastatic breast cancer will be randomly assigned to one of two scan schedules. The goal is to see if th…

This study is looking for early warning signs of serious side effects from the breast cancer drug T-DXd. Researchers will collect blood samples from 84 people with advanced breast cancer before and during treatment. The goal is to find markers that could predict who is at risk fo…

This study is testing a blood test called DiviTum TKa to see if it can spot early signs that hormone-receptor-positive metastatic breast cancer is becoming resistant to treatment. About 100 people starting or changing their hormone therapy or CDK4/6 inhibitor drugs will give bloo…

This study looks at whether starting with a lower dose of CDK4/6 inhibitor pills (palbociclib or ribociclib) and slowly increasing the dose helps older adults (65+) with metastatic breast cancer tolerate side effects better and stay on treatment longer. About 500 participants wil…

This study looks at whether taking endocrine therapy in the morning or evening makes a difference for people with metastatic breast or prostate cancer. About 50 participants will be randomly assigned to take their medication at one of these times. The main goal is to see if a lar…

This study is creating a registry (a database) for people with a rare type of breast cancer called invasive lobular carcinoma that has spread. Researchers will collect information from about 12 participants to develop a tool that better measures how the disease responds to treatm…

This study explores whether certain genetic variations can predict severe side effects from powerful breast cancer drugs called antibody-drug conjugates. Researchers will analyze blood samples from 70 patients with advanced breast cancer to see if a specific gene (UGT1A1) is link…

This study aims to understand if emotional distress (like anxiety or depression) impacts how well first-line therapy works in people with metastatic breast cancer. Researchers will follow 1,000 patients starting standard treatments based on their cancer subtype. The goal is to se…

This study is testing whether routine brain MRI scans can detect breast cancer that has spread to the brain in patients with certain types of advanced breast cancer. Researchers will follow 214 participants over time to see if early detection improves quality of life and reduces …

This study is collecting tissue samples from 1,050 people with early or metastatic breast cancer to create a detailed map of fat storage and protein patterns inside cancer cells. The goal is to better understand how different breast cancer subtypes behave. Participants provide sa…

This study is looking for blood markers that could help predict where breast cancer might spread. Researchers will measure two types of markers in the blood of 160 women: some with cancer that has spread, some with early-stage cancer, and some healthy. The goal is to develop a no…

This study looks at whether it is possible and acceptable to take multiple tissue samples (biopsies) from different tumor sites over time in people with metastatic breast cancer. The goal is to understand how the cancer changes and becomes resistant to treatment. Researchers will…

This study follows 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these treatments control the cancer in real-world settings. The goal is to gather information…

This study enrolls 5,000 people with metastatic breast cancer to analyze their tumor and blood samples for genetic markers. The goal is to identify which patients might benefit from specific targeted therapies and connect them to appropriate clinical trials. Participants continue…

This study is looking at a specific type of breast cancer that has spread (metastatic) and is HER2-negative but has androgen receptors (AR-positive). Researchers want to see if a special PET/CT scan that detects a protein called PSMA can help predict which cancers will not respon…

This study observes 2000 people with advanced breast cancer to learn how the disease changes over time and why some treatments stop working. Researchers collect tumor samples and health data to find new markers that predict treatment response. The goal is to improve future therap…

This study looks at how certain genetic changes (ESR1 mutations) appear in the blood of people with metastatic breast cancer. Researchers will compare patients who have had prior treatments with those who haven't. The goal is to better understand why some cancers become resistant…

This study is testing whether a personalized lab test, called a tumorogram, can help choose the best treatment for people with metastatic breast cancer. Researchers take a small sample of the tumor and grow it in the lab to create a 'tumor avatar.' They then test different drugs …